Review Article

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol

Authors: Alyssa S. Laun, Sarah H. Shrader, Kevin J. Brown, Zhao-Hui Song
DOI: 10.1038/s41401-018-0031-9
Received: 15 January 2018
Accepted: 17 April 2018
Advance online: 25 June 2018

Abstract

The G protein-coupled receptors 3, 6, and 12 (GPR3, GPR6, and GPR12) comprise a family of closely related orphan receptors with no confirmed endogenous ligands. These receptors are constitutively active and capable of signaling through G protein-mediated and non-G protein-mediated mechanisms. These orphan receptors have previously been reported to play important roles in many normal physiological functions and to be involved in a variety of pathological conditions. Although they are orphans, GPR3, GPR6, and GPR12 are phylogenetically most closely related to the cannabinoid receptors. Using β-arrestin2 recruitment and cAMP accumulation assays, we recently found that the nonpsychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, GPR6, and GPR12. This discovery highlights these orphan receptors as potential new molecular targets for CBD, provides novel mechanisms of action, and suggests new therapeutic uses of CBD for illnesses such as Alzheimer’s disease, Parkinson’s disease, cancer, and infertility. Furthermore, identification of CBD as a new inverse agonist for GPR3, GPR6, and GPR12 provides the initial chemical scaffolds upon which potent and efficacious agents acting on these receptors can be developed, with the goal of developing chemical tools for studying these orphan receptors and ultimately new therapeutic agents.
Keywords: orphan receptors; GPR3; GPR6; GPR12; cannabidiol; inverse agonist; eurite outgrowth; Alzheimer’s disease; neuropathic pain; obesity; infertility

Article Options

Download Citation

Cited times in Scopus